|
|
 |
|
Viewing report
|
|
|
|
Organic and Medicinal Chemistry in Drug Discovery: Pharma's Intelligent Design
Drug and Market Development Publishing, Nov 2005, Pages: 176
The pharmaceutical industry continues to deal with challenges to improve productivity in getting new drugs to market. Industrialization of drug discovery greatly increased the capacity of companies to screen new compounds, thereby increasing the demand for lead-like compounds beyond the capacities of organic and medicinal chemistry departments to respond. The advent of combinatorial chemistry satisfied the demand for more compounds, but overall results in terms of productivity remained disappointing. Based on experience with combinatorial chemistry, pharmaceutical companies have evolved new strategies and methods for increasing the quality, and not just the quantity, of their compound libraries. Improvements have been made in downstream hit-to-lead and lead optimization as well.
The 'Organic and Medicinal Chemistry in Drug Discovery' report analyzes the methods and technologies currently used to craft compound collections as well as the products and services available in support of pharma's chemistry programs. This report critically evaluates both existing and emerging technologies for organic synthesis and compound design. In addition, the technology and market trends in organic and medicinal chemistry for drug discovery are discussed in depth, and current sales and market projections for outsourcing products and services are also provided. This report offers the views of key industry participants on the state of and future prospects for organic and medicinal chemistry in drug discovery. This data was obtained through a proprietary market survey. In addition to the survey, in-depth interviews were conducted with chemists and managers in pharma, biopharma, and vendor organizations. The inclusion of the history and evolution of organic and medicinal chemistry in pharma provides perspective on current approaches and future directions.
Questions Answered
- What are the key new technologies influencing organic and medicinal chemistry in pharma today?
- Who are the key players addressing pharma's needs and how are they approaching the market in terms of technologies and business models?
- How do experts in the field view the current chemistry landscape and where do they see gaps for future improvement?
- What is the size of the current market for chemistry goods and services, and how fast is it likely to grow over the next five years?
- How will pharma expenditures on internal and outsourced chemistry change in the near future?
- Who are the key company players in chemistry outsourcing?
- How does pharma grow and manage its compound resources today?
Key Reasons to Purchase
- This report enables managers to understand the range of technologies and approaches employed as a guide to choosing their outsource vendors.
- Technologies and methods for generating compound libraries and for doing downstream synthesis are in rapid flux. Concepts of drug-likeness and lead-likeness are driving changes in the ways chemists conceive new structures and execute their synthesis. This report will help companies to understand these concepts and the methods for implementation in order assess their value the organization.
- Screening libraries need to reflect both depth and diversity. This report examines the varying approaches drug discovery organizations and vendors take in addressing this critical issue.
- The report examines the importance and relevance of topics such as diversity-oriented synthesis, dynamic combinatorial chemistry, and chemogenomics in advancing the effectiveness of drug discovery.
About the Author
Ken Rubenstein, Ph.D.With more than 20 years technical and market consulting experience, Ken Rubenstein, principal of the Lion Consulting Group, is the author of more than 30 published market and industry research reports, and has consulted for more than 50 biotechnology companies and venture capital firms in areas ranging from opportunities assessment to product development.Dr. Rubenstein played key research and development roles for the Syva Company up to the vice president level. During 12 years with Syva, he co-invented their highly successful EMIT immunoassay technology, developed numerous products, and directed both project management and strategic planning activities.Dr. Rubenstein received his doctorate in organic chemistry from the University of Wisconsin, and did two years post-doctoral training in microbiology and molecular biology at the University of Pennsylvania School of Medicine.
Customers who bought this item also bought
The Organic Chemistry of Drug Synthesis, Volume 7
Fluorine in Medicinal Chemistry and Chemical Biology
Medicinal Chemistry: An Introduction, 2nd Edition
Fundamentals of Medicinal Chemistry
Bioorganic and Medicinal Chemistry of Fluorine
Tomorrow's Chemistry Today: Concepts in Nanoscience, Organic Materials and Environmental Chemistry
Organic Chemistry, 9th Edition
Introduction to Materials Chemistry
Combinatorial Chemistry: Powerful New Tool for Discovery and Product Development. 2nd Edition (Technical Insights)
U.S. Combinatorial Chemistry Libraries Market
Outsourcing Chemistry Services Made Easy
Computational Organic Chemistry
|
|
|
|
